News
MyChesCo on MSN1d
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...
Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...
Stocktwits on MSN2d
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On StockShort interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased ...
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO ...
12d
Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...
13d
Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback